Get the Stockscreener App
14.27
0.21%
0.03
After Hours:
14.25
-0.02
-0.14%
Amicus Therapeutics Inc stock is traded at $14.27, with a volume of 8.08M.
It is up +0.21% in the last 24 hours and up +46.66% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$14.24
Open:
$14.245
24h Volume:
8.08M
Relative Volume:
0.93
Market Cap:
$4.41B
Revenue:
$571.16M
Net Income/Loss:
$-38.10M
P/E Ratio:
-116.49
EPS:
-0.1225
Net Cash Flow:
$-48.91M
1W Performance:
+0.14%
1M Performance:
+46.66%
6M Performance:
+139.83%
1Y Performance:
+53.28%
1-Day Range:
$14.23
$14.27
1-Week Range:
$14.23
$14.28
52-Week Range:
$5.51
$14.36
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.27 | 4.40B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
BioMarin's $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance - FinancialContent
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
H.C. Wainwright: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Insider Monkey
H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver - Finviz
Amicus Therapeutics Earnings Notes - Trefis
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN) - Seeking Alpha
Can Religare Enterprises Limited Stock Deliver Alpha in a Choppy MarketFundamental Stock Analysis & Free Navigate Market With Precision - earlytimes.in
Amicus Therapeutics (NASDAQ:FOLD) Nasdaq 100 Index Precision Biotech - Kalkine Media
BioMarin to Acquire Amicus Therapeutics for $4.8B - Contract Pharma
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
FOLD: Analyst Downgrade and Price Target Adjustments | FOLD Stoc - GuruFocus
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by Leerink Partners - MarketBeat
Leerink Downgrades Amicus Therapeutics to Market Perform From Outperform, Adjusts Price Target to $14.50 From $17 - marketscreener.com
Leerink Partners downgrades Amicus Therapeutics stock on BioMarin acquisition By Investing.com - Investing.com UK
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
Amicus Therapeutics, Inc. $FOLD Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Best Biotech Stocks To Watch TodayDecember 21st - MarketBeat
BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight (NASDAQ:BMRN) - Seeking Alpha
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc.FOLD - The AI Journal
Voya Investment Management LLC Sells 90,062 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Its Recent Share Price Rally - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Amicus Therapeutics, Inc.,M&A CallSlideshow (NASDAQ:BMRN) 2025-12-24 - Seeking Alpha
John F. Crowley: A Legacy For Rare Diseases - Oncodaily
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
Is the Market Bullish or Bearish on Amicus Therapeutics Inc? - Benzinga
Published on: 2025-12-24 04:19:57 - Bollywood Helpline
Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,642 Shares - MarketBeat
Amicus Therapeutics Executive Sells Shares Under Trading Plan - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion - New Jersey Business Magazine
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know - Finviz
BioMarin To Buy Amicus For $4.8 Billion - Pulse 2.0
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSECWAN), Katapult Holdings, Inc. (NasdaqKPLT), Janus Henderson Group plc (NYSEJHG), Amicus Therapeutics, Inc. (Nasdaq - GlobeNewswire Inc.
What's Going On With BioMarin Stock On Tuesday? - Sahm
What's Going On With BioMarin Stock On Tuesday? - Benzinga
Promising Biotech Stocks To Follow NowDecember 19th - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Downgraded by Citigroup to "Hold" - MarketBeat
Narrow-Moat BioMarin's $4.8 Billion Deal for Amicus Therapeutics Expands Rare Disease Portfolio - Morningstar
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition - Finviz
Citigroup downgrades Amicus Therapeutics (FOLD) - MSN
BioMarin to acquire Amicus Therapeutics for $4.8 billion By Investing.com - Investing.com Nigeria
Amicus Therapeutics Inc. (FOLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Amicus Therapeutics (NASDAQ:FOLD) Sees Strong Trading VolumeHere's Why - MarketBeat
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025) - ts2.tech
American biotech company BioMarin acquires Amicus Therapeutics for $4.8 billion - AKM.RU
BioMarin: Amicus Buyout Sparks My Enthusiasm (NASDAQ:BMRN) - Seeking Alpha
The Biotech Growth Trust PLCBioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics - Research Tree
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B - sharewise.com
BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push - Yahoo Finance
BioMarin ends year with $4.8bn play for Amicus - RamaOnHealthcare
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):